ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Bart Leroy, MD, PhD, elucidates complications that may occur following gene therapy with Luxturna.
In most cases adverse reactions are limited to manageable inflammation, but some studies have shown that 15% to 25% of eyes treated with Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) have developed chorioretinal atrophy, Leroy explained.
“People have a tendency to lump [chorioretinal atrophy] together, but I prefer to divide it up into three types of chorioretinal atrophy that I see may have